In the treatment of advanced ALK/ROS-positive NSCLC patients with drug-resistant mutations, lorlatinib, as a sequential drug in the treatment of brigatinib and alectinib, can significantly exert its therapeutic activity, and patients have good tolerance to lorlatinib without serious adverse reactions (145). Here, ALK is linked to non-small cell lung carcinoma.